Roche (OTCQX:RHHBY) shares closed ~4% higher in Europe on Monday as the maker of Ocrevus multiple sclerosis therapy announced two Phase 3 trial successes for fenebrutinib, its new experimental drug ...

Trial tests drug against relapsing form of the disease Drug candidate as effective as Roche's Ocrevus in a separate study Fenebrutinib could bring in over $1 billion in annual peak sales FRANKFURT, ...

Thousands of people in England with a type of multiple sclerosis (MS) are set to benefit from a new treatment on the NHS. Natalizumab, which is given every four weeks as an infusion or injection, has ...

Roche said its fenebrutinib drug candidate met primary goals in two late-stage trials for multiple sclerosis, reducing attacks or delaying disability progression in two different forms of the disease.

Bayer recently received FDA approval for a connected auto-injector for relapsing-remitting multiple sclerosis medication and companion app. The device is called the Betaconnect Electronic Autoinjector ...